REG - Alliance Pharma PLC - Directorate Changes

Alliance PharmaAnnouncement

18/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220518:nRSR8511La&default-theme=true

RNS Number : 8511L  Alliance Pharma PLC  18 May 2022

 

 For immediate release  18 May 2022

 

 

 

ALLIANCE PHARMA

("Alliance" or the "Group")

 

Directorate changes

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces
that, in line with good corporate governance, David Cook, Alliance's Chair,
will be stepping down next year, following the AGM in May 2023, after serving
on the Board for nine years.

 

Jo LeCouilliard, currently a Non-Executive Director on the Board of Alliance,
will become Chair following the AGM in May 2023.

 

Jo LeCouilliard joined Alliance as a Non-Executive Director on 1 January 2019.
She brings over 25 years of international healthcare management experience
through her career at GlaxoSmithKline where, amongst other roles, she headed
the US vaccines business and the Asia Pacific Pharmaceuticals business. Jo is
a Chartered Accountant and is currently a Non-Executive Director at Circassia
Group plc, Indivior plc and Recordati S.p.a.

 

David Cook commented: "Alliance has developed significantly over the time I
have been with the business, building an international footprint and
transitioning to focus on consumer healthcare brands. I am confident that the
Company has a bright future, led by an outstanding senior management team. Jo
has been an invaluable Board member over the past three and a half years and
we are delighted that she has agreed to chair the Board as the Company
continues on its growth trajectory. I look forward to working closely with her
during my remaining time at Alliance."

 

Jo LeCouilliard commented: "I am delighted to be taking on the position of
Chair following next year's AGM. I have been really impressed by Alliance's
strong management team and strategy over my last three and a half years on the
Board. The Company has successfully executed a number of strategic consumer
healthcare acquisitons and has built a solid international infrastructure. I
look forward to leading the Board in taking the Company forward."

 

 

For further information:

 

 Alliance Pharma plc                                                       + 44 (0)1249 466966
 Cora McCallum, Head of Investor Relations & Corporate Communications      + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                  + 44 (0)20 7466 5000
 Mark Court / Sophie Wills / Hannah Ratcliff
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Numis Securities Limited                                                  + 44 (0)20 7260 1000
 Nominated Adviser: Freddie Barnfield / Duncan Monteith
 Corporate Broking: James Black

 Investec Bank plc                                                         + 44 (0)20 7597 5970
 Corporate Finance: Daniel Adams
 Corporate Broking: Patrick Robb

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our
purpose is to improve the lives of consumers and patients through making
available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented
by a smaller Prescription Medicines business. In total, we hold marketing
rights to around 80 brands, with revenues generated from a mix of direct,
distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics operations, we remain asset-light
and focused on maximising the value of our brands.

For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUWWAUPPGMM